Completed PHASE2 INTERVENTIONAL 2-arm NCT03923933

Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial

Sponsor: Hospital General de México Dr. Eduardo Liceaga

Updated 9 times since 2019 Last updated: Nov 4, 2020 Started: Jun 18, 2019 Primary completion: Oct 28, 2019 Completion: Oct 28, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03923933, this PHASE2 trial focuses on Renal Insufficiency, Chronic and remains completed. Sponsored by Hospital General de México Dr. Eduardo Liceaga, it has been updated 9 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Dec 2020 — Jan 2021 [monthly]

Completed PHASE2

Phase: PHASE4 → PHASE2

▶ Show 4 earlier versions

Apr 2020 — Dec 2020 [monthly]

Completed PHASE4
Nov 2019 — Apr 2020 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jul 2019 — Nov 2019 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
May 2019 — Jul 2019 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital General de México Dr. Eduardo Liceaga

Data source: Hospital General de México Dr. Eduardo Liceaga

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mexico City, Mexico